FY2017 Earnings Estimate for Gilead Sciences, Inc. (GILD) Issued By Leerink Swann
Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Leerink Swann lifted their FY2017 earnings per share (EPS) estimates for shares of Gilead Sciences in a research note issued on Thursday. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will post earnings per share of $8.82 for the year, up from their previous forecast of $8.37. Leerink Swann currently has a “Market Perform” rating and a $85.00 price objective on the stock. Leerink Swann also issued estimates for Gilead Sciences’ Q4 2018 earnings at $1.72 EPS and FY2019 earnings at $6.84 EPS.
A number of other equities research analysts have also weighed in on GILD. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday. Wells Fargo & Co raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $79.02 to $96.00 in a research report on Tuesday. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Thursday. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Finally, Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research report on Wednesday. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $85.53.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.75 EPS.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Keel Point LLC raised its holdings in shares of Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 12 shares during the last quarter. Paradigm Financial Advisors LLC raised its holdings in shares of Gilead Sciences by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares during the last quarter. Princeton Portfolio Strategies Group LLC raised its holdings in shares of Gilead Sciences by 0.4% during the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares during the last quarter. Arrow Financial Corp raised its holdings in shares of Gilead Sciences by 0.3% during the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 45 shares during the last quarter. Finally, Auxier Asset Management raised its holdings in shares of Gilead Sciences by 1.4% during the second quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock valued at $479,000 after purchasing an additional 96 shares during the last quarter. 75.95% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold 591,666 shares of company stock valued at $44,466,567 over the last ninety days. Corporate insiders own 1.30% of the company’s stock.
The company also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.56%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/19/fy2017-earnings-estimate-for-gilead-sciences-inc-gild-issued-by-leerink-swann.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.